A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy Geoffrey M. Forbes, Marian J. Sturm, Rupert W. Leong, Miles P. Sparrow, Dev Segarajasingam, Adrian G. Cummins, Michael Phillips, Richard P. Herrmann Clinical Gastroenterology and Hepatology Volume 12, Issue 1, Pages 64-71 (January 2014) DOI: 10.1016/j.cgh.2013.06.021 Copyright © 2014 AGA Institute Terms and Conditions
Figure 1 Study overview. Clinical Gastroenterology and Hepatology 2014 12, 64-71DOI: (10.1016/j.cgh.2013.06.021) Copyright © 2014 AGA Institute Terms and Conditions
Figure 2 CDAI score of 15 subjects at study entry and at day 42. Broken lines indicate patients without clinical response. Clinical Gastroenterology and Hepatology 2014 12, 64-71DOI: (10.1016/j.cgh.2013.06.021) Copyright © 2014 AGA Institute Terms and Conditions
Figure 3 Mean CDAI by study visit (n = 15). Restricted cubic spline mean regression line with 95% confidence intervals (shaded area). Data points for all patients are shown. Clinical Gastroenterology and Hepatology 2014 12, 64-71DOI: (10.1016/j.cgh.2013.06.021) Copyright © 2014 AGA Institute Terms and Conditions